The Twice-Yearly Shot Hailed as the Closest Thing to an HIV Vaccine — and the Access Fight Behind It

A twice-yearly injection is being described as the closest thing the world has ever had to an HIV vaccine, yet the question of who will actually receive it has opened a far larger debate about public money, pharmaceutical power, drug pricing and the retreat of global health funding.

The preventative treatment, which requires only two doses a year, represents a potential turning point in the decades-long battle against HIV. Unlike a traditional vaccine, which trains the immune system to repel a virus before exposure, this approach works by delivering antiretroviral medication into the body over an extended period, offering sustained protection for people at substantial risk of infection. Its long-acting design sets it apart from the daily pills that have anchored HIV prevention for years.

For public health experts, the appeal is straightforward. Daily oral regimens have proven highly effective when taken consistently, but adherence remains a persistent obstacle. People who face stigma, unstable housing, or difficulty accessing clinics often struggle to maintain a daily routine, leaving gaps in protection precisely when they need it most. An injection administered just twice annually could remove much of that burden, particularly in regions where health systems are stretched thin.

Supporters argue that the shot could dramatically alter the trajectory of the epidemic, which has claimed tens of millions of lives over four decades. In communities where new infections continue to climb, a long-acting option might reach people who have so far been left behind by existing prevention tools.

Yet the enthusiasm surrounding the breakthrough has been shadowed by an equally urgent question: who will be able to afford it? The pricing of new pharmaceuticals has long been a flashpoint in global health, and this case is no exception. Without deliberate intervention, advocates warn, the injection could remain out of reach for the very populations that stand to benefit most.

At the centre of the dispute is the relationship between public financing and private profit. Governments and charitable foundations often fund the basic research that makes discoveries possible, only to see the resulting products priced in ways that limit access. Critics contend that when taxpayers help underwrite innovation, they should share in its rewards through affordable access rather than facing high costs at the pharmacy.

The debate is unfolding against a difficult financial backdrop. Global health budgets have been contracting, with major donors scaling back commitments that once supported HIV treatment and prevention across low- and middle-income countries. Shrinking funding leaves governments and international agencies with less room to negotiate bulk purchases or subsidise new medicines, compounding the challenge of rolling out an expensive new intervention.

Pharmaceutical companies, for their part, argue that prices reflect the substantial costs of research, development, and manufacturing, and that sustainable profits are necessary to fund future innovation. They also note that tiered pricing and voluntary licensing arrangements have widened access to other treatments in the past. Whether similar mechanisms will apply to this injection remains a central point of contention.

The access question also carries a geographic dimension. If wealthy nations secure supply first, as has happened with other medical breakthroughs, poorer countries could wait years before doses arrive. During that gap, transmission would continue, and the promise of a transformative tool would go unrealised for those facing the highest risk.

Public health campaigners have therefore called for early agreements on manufacturing capacity, affordable pricing, and equitable distribution. They argue that speed matters not only for individuals but for the wider effort to end the epidemic, since every delay allows new infections to accumulate.

Al Jazeera’s Mikail Malik examines this fight over access in a NewsFeed report, exploring the competing pressures that will determine how widely the injection is used and who is left waiting. The story raises broader questions about how the world prioritises health, who benefits from scientific progress, and whether the rhetoric of global solidarity can survive contact with commercial and political realities.

The stakes extend beyond HIV. The outcome of this debate could set a precedent for how future long-acting prevention technologies — and other costly innovations — are shared. If the world can find a way to deliver this injection equitably, it would demonstrate that scientific advances need not deepen existing inequalities. If it cannot, the gap between discovery and delivery will widen once again.

For now, the injection stands as both a symbol of possibility and a test of will. It has been called the closest thing to an HIV vaccine, a phrase that captures the hope it inspires. The more difficult sentence to finish is the one that follows: whether the millions who need it will ever hold it in their hands.